Vijay Pande, once a Stanford chemistry professor, transformed from an academic figure into a prominent investor after joining a16z a dozen years ago. Marc Andreessen and Ben Horowitz, who initially avoided healthcare investments, recognized the potential in the sector and entrusted Pande with managing a16z’s healthcare bets, which eventually grew to nearly $4 billion in assets. This success, however, led Pande to pivot significantly in June of last year when he left a16z to found VZVC, a venture firm that focuses on a handful of concentrated bets annually, employs no associates, and heavily relies on AI for operations. Pande’s shift reflects a broader rethinking of investment strategies in the AI-driven biotech space, where data scarcity and siloed research pose unique challenges. Source: techcrunch

Pande emphasized that biology is transitioning from a science of discovery to an engineered field, where AI and machine learning are enabling more precise drug development. He noted that traditional drug development often relied on chance, but AI can now help identify targets for specific diseases, design drugs, and even assist in clinical trials. While synthetic data has reduced the need for large trial populations, the cost of trials remains high, with only a 20% chance of success from the first trial to the end of the third. Pande argued that animal models are not reliable predictors of human responses, and AI models, though not perfect, offer a significant improvement. Source: techcrunch

Pande also highlighted the challenges of data sharing in biotech, noting that unlike text data, biological data cannot be easily scraped from the internet, making it difficult for companies to build shared datasets. This data scarcity creates silos, similar to the challenges faced by doctors in different specialties who often don’t collaborate. Pande sees potential in building open-source foundation models for biological data, akin to the impact of open-source large language models. He is also involved with companies like Genesis Therapeutics and Insitro, and is incubating a new venture with a founder he has known for 20 years. Source: techcrunch

Source: techcrunch